# PT-141 FAQ: Dosage, Half-Life, Mechanism, and Use (Bremelanotide)

> PT-141 FAQ: what it is, the approved bremelanotide dose, half-life, onset, mechanism, receptors, and approved vs off-label use — direct, cited answers.

Short, cited answers on dosage, half-life, mechanism, and the line between approved and off-label use.

## What is the PT-141 dosage?

In the record, the only approved dose is 1.75 mg subcutaneous, as needed, for premenopausal women with HSDD [11]. It is reported here as a label finding, not a protocol for any reader. Material sold as research chemical is a laboratory material, not the approved drug.

## How much PT-141 should I take?

No human dosing recommendation is made here. The studied and labeled dose is 1.75 mg subcutaneous as needed, with a maximum of one dose per 24 hours and no more than eight per month, in the approved population only [11]. This site recommends no dose to anyone.

## How much PT-141 to inject?

The approved label specifies 1.75 mg subcutaneously for premenopausal women with HSDD [11]. That is a documented finding, not advice. Material sold as "PT-141 research chemical" is for laboratory use only and is not the approved finished drug product.

## What is the PT-141 dosage for women?

The FDA-approved bremelanotide dose for premenopausal women with HSDD is 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity [11]. The frequency cap is one dose per 24 hours and no more than eight per month [11]. Reported as a label finding.

## How do you reconstitute PT-141?

The approved product is a prefilled single-dose subcutaneous autoinjector, not a reconstituted powder [11]. There is nothing to mix. Reconstitution applies only to research-chemical material, which is a laboratory procedure outside the approved drug and outside this site's scope.

## How do you take PT-141?

Per the label, bremelanotide is self-administered as a subcutaneous injection in the abdomen or thigh, as needed before anticipated sexual activity, in the approved population [11]. This is a description of the label, not an instruction to use it.

## How often can you take PT-141?

The label limits dosing to no more than one dose per 24 hours and no more than eight doses per month [11]. Reported as a label finding. The frequency cap matters because higher-frequency exposure is where appetite, blood-pressure, and pigment effects become most relevant [12].

## What is the approved bremelanotide dose?

1.75 mg subcutaneous, as needed — maximum one dose per 24 hours and eight per month — for acquired, generalized HSDD in premenopausal women [11]. That single dose and indication define the entire approval (NDA 210557, June 2019) [11].

## How long does PT-141 last?

With a terminal half-life of roughly 2.7 hours after subcutaneous dosing, plasma levels fall over a few hours, so it is used as needed rather than daily [11]. One fMRI study reported a central desire effect for up to 24 hours, which outlasts the plasma curve [5].

## How long does PT-141 take to work?

The label directs dosing at least 45 minutes before activity; median Tmax is about 0.5-1.0 hours after subcutaneous injection [11]. Early intranasal work in men reported a first erectile response at roughly 30 minutes [6]. Peak exposure and first effect both land within the first hour.

## What is the half-life of PT-141?

Terminal half-life is approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous administration per the US prescribing information [11]. Early intranasal studies in men reported a shorter 1.85-2.09 hours [6]. The subcutaneous figure is the authoritative one.

## How long does PT-141 stay in your system?

Given the ~2.7 hour half-life, the drug clears over several hours rather than days [11]. Radiolabeled excretion is about 64.8% renal and 22.8% fecal, with clearance around 6.5 L/hr and a volume of distribution near 25.0 L [11].

## Does PT-141 nasal spray work?

Early intranasal studies in men showed a dose-dependent erectile response above 7 mg [6]. But the intranasal route was discontinued for pharmacokinetic variability, and the approved product is subcutaneous [6][11]. The nasal form showed an effect yet was not the form that reached approval.

## What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide melanocortin (MC3R/MC4R) receptor agonist that acts centrally on sexual desire and arousal [1][11]. It is approved for one use: premenopausal HSDD [11].

## What is PT-141 peptide?

The PT-141 peptide is a seven-amino-acid cyclic peptide analogue of alpha-MSH, with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH [1]. The cyclic lactam structure makes it more stable than linear melanocortin peptides [1].

## What does the PT-141 peptide do?

It activates central melanocortin MC4R/MC3R receptors in the hypothalamus and limbic system, engaging dopaminergic circuits tied to sexual motivation rather than acting on blood flow [1][11]. The effect is on desire, not on vascular smooth muscle [12].

## What is PT-141 used for?

Bremelanotide is FDA-approved only for acquired, generalized HSDD in premenopausal women [11]. All other uses — men, erectile dysfunction, postmenopausal women, sexual performance — are off-label and investigational, not supported by the approval [11][12].

## Is PT-141 the same as bremelanotide?

Yes. PT-141 is the development and research designation; bremelanotide is the international nonproprietary name for the same melanocortin receptor agonist [1][11]. Both refer to the identical molecule, CAS 189691-06-3 [1].

## What is bremelanotide?

Bremelanotide is the approved melanocortin receptor agonist (approved June 2019, NDA 210557), administered as a 1.75 mg subcutaneous injection as needed for premenopausal HSDD [11]. It is the international nonproprietary name for PT-141 [1].

## How does PT-141 work?

It stimulates MC4R in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways of sexual desire [1][11]. Unlike PDE-5 inhibitors, it works centrally on the brain's motivation circuitry, not on vascular smooth muscle [12].

## What receptors does PT-141 act on?

Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R activity [1][5]. These are central-nervous-system melanocortin receptor subtypes concentrated in the hypothalamus and limbic system [11].

## Does PT-141 work through the brain or through blood flow?

Through the brain. It acts on central melanocortin circuits governing sexual motivation, which is mechanistically distinct from the peripheral vascular action of PDE-5 inhibitors [1][12]. Human fMRI data support the central account [5].

---

A cold reading of the bremelanotide record — the trial numbers, the label warnings, and the field reports walled off as unverified; no clinic in the dark behind it, and nothing here dispensed, priced, or sold.